NewLink Genetics Corp (NASDAQ:NLNK) has received an average recommendation of “Buy” from the nine brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $25.67.
A number of equities analysts have recently issued reports on the company. ValuEngine downgraded NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 target price on shares of NewLink Genetics in a research report on Monday, September 25th. Finally, Stifel Nicolaus lifted their target price on NewLink Genetics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, November 3rd.
NewLink Genetics (NASDAQ NLNK) traded up $0.18 during mid-day trading on Tuesday, hitting $8.62. The stock had a trading volume of 471,612 shares, compared to its average volume of 955,777. The stock has a market cap of $312.23, a P/E ratio of -3.53 and a beta of 1.10. NewLink Genetics has a 52-week low of $5.90 and a 52-week high of $25.17.
NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. research analysts forecast that NewLink Genetics will post -2.65 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NLNK. Perceptive Advisors LLC purchased a new position in NewLink Genetics during the third quarter valued at $4,581,000. Candriam Luxembourg S.C.A. lifted its position in NewLink Genetics by 337.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock valued at $3,339,000 after purchasing an additional 253,000 shares in the last quarter. Ameriprise Financial Inc. lifted its position in NewLink Genetics by 207.1% during the third quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock valued at $3,176,000 after purchasing an additional 210,360 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in NewLink Genetics during the third quarter valued at $1,819,000. Finally, GSA Capital Partners LLP lifted its position in NewLink Genetics by 653.7% during the third quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock valued at $1,345,000 after purchasing an additional 114,620 shares in the last quarter. Institutional investors own 52.63% of the company’s stock.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.